Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 16(4): e0250354, 2021.
Article in English | MEDLINE | ID: mdl-33872333

ABSTRACT

Constipation is a common condition that affects individuals of all ages, and prolonged constipation needs to be prevented to avoid potential complications and reduce the additional stress on individuals with pre-medical conditions. This study aimed to evaluate the effects of heat-inactivated Lactobacillus plantarum (HLp-nF1) on loperamide-induced constipation in rats. Constipation-induced male rats were treated orally with low to high doses of HLp-nF1 and an anti-constipation medication Dulcolax for five weeks. Study has 8 groups, control group; loperamide-treated group; Dulcolax-treated group; treatment with 3.2 × 1010, 8 × 1010 and 1.6 × 1011, cells/mL HLp-nF1; Loperamide + Dulcolax treated group. HLp-nF1 treated rats showed improvements in fecal pellet number, weight, water content, intestinal transit length, and contractility compared to the constipation-induced rats. Also, an increase in the intestine mucosal layer thickness and the number of mucin-producing crypt epithelial cells were observed in HLp-nF1-treated groups. Further, the levels of inflammatory cytokines levels were significantly downregulated by treatment with HLp-nF1 and Dulcolax. Notably, the metagenomics sequencing analysis demonstrated a similar genus pattern to the pre-preparation group and control with HLp-nF1 treatment. In conclusion, the administration of >3.2 × 1010 cells/mL HLp-nF1 has a positive impact on the constipated rats overall health.


Subject(s)
Constipation/therapy , Gastrointestinal Transit/drug effects , Intestinal Mucosa/drug effects , Lactobacillus plantarum/physiology , Laxatives/pharmacology , Metagenome , Actinobacteria/genetics , Actinobacteria/growth & development , Actinobacteria/isolation & purification , Animals , Bacteroidetes/genetics , Bacteroidetes/growth & development , Bacteroidetes/isolation & purification , Bisacodyl/pharmacology , Constipation/chemically induced , Constipation/microbiology , Cyclooxygenase 2/genetics , Cyclooxygenase 2/metabolism , Feces/microbiology , Firmicutes/genetics , Firmicutes/growth & development , Firmicutes/isolation & purification , Gastrointestinal Transit/physiology , Gene Expression/drug effects , Hot Temperature , Interleukin-1beta/genetics , Interleukin-1beta/metabolism , Interleukin-6/genetics , Interleukin-6/metabolism , Intestinal Mucosa/microbiology , Loperamide/adverse effects , Male , Microbial Viability , Proteobacteria/genetics , Proteobacteria/growth & development , Proteobacteria/isolation & purification , RNA, Ribosomal, 16S/genetics , Rats , Rats, Sprague-Dawley , Treatment Outcome , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism , Verrucomicrobia/genetics , Verrucomicrobia/growth & development , Verrucomicrobia/isolation & purification
SELECTION OF CITATIONS
SEARCH DETAIL